Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M E GelsH Schraffordt Koops

Abstract

A wait-and-see policy for patients with stage I nonseminomatous testicular germ cell tumors (NSTGCT) was evaluated in a prospective study. The frequency and time of recurrence, detection of recurrence, and presence of unfavorable prognostic factors were investigated. During the period 1982 to 1992, 154 patients with stage I NSTGCT (median age, 29 years) underwent orchidectomy and were monitored at follow-up evaluation with physical examinations, alfafetoprotein (AFP) and beta-human choriogonadotropin (hCG) levels, chest x-rays (CXR), and computed tomographic (CT) scans of the abdomen and chest. Multivariate logistic regression analyses were performed to identify prognostic factors. During a median follow-up period of 7 years (range, 2 to 12), recurrence was found in 42 patients (27.3%). All cases of recurrence were detected within 2 years, 90% in the first year after orchidectomy. In 29 patients (69.0%), recurrence was detected in the abdominal lymph nodes. Nine patients (21.4%) had metastases in the retroperitoneum and mediastinum and/or lungs, and four patients (9.6%) had metastases only in the mediastinum or lungs. The majority of recurrences (97.6%) were detected by tumor markers and CT scans. Recurrence was related to the ...Continue Reading

Citations

Jun 1, 1997·Annals of Surgical Oncology·J P van BastenH Schraffordt Koops
Dec 10, 1999·Seminars in Surgical Oncology·D J SonneveldH J Hoekstra
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter AlbersUNKNOWN German Testicular Cancer Study Group
May 20, 2003·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Gedske DaugaardMikael Rørth
Sep 30, 2003·Medical and Pediatric Oncology·Margherita Lo CurtoPaolo Tamaro
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan OldenburgSophie D Fosså
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hua-yin YuChristopher S Saigal
Jun 17, 2014·Expert Review of Anticancer Therapy·Sumit Isharwal, Michael C Risk
Jan 28, 2017·Indian Journal of Surgical Oncology·Puneet Ahluwalia, Gagan Gautam
Oct 1, 2019·Nuclear Medicine Communications·Cigdem SoydalNuriye Ozlem Kucuk
Jul 21, 1998·Cancer·D RaysonR L Richardson
Oct 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yvonne VergouweJ Dik F Habbema
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald de Wit, Karim Fizazi
Aug 19, 2005·Current Treatment Options in Oncology·Andrew J Stephenson, Joel Sheinfeld
Oct 21, 2009·BJU International·Alvaro ZunigaMichael A S Jewett
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Torgrim TandstadOlbjørn Klepp
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carvell T NguyenAndrew J Stephenson
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R Feldman
Jul 24, 1997·The New England Journal of Medicine·G J Bosl, R J Motzer
May 16, 2002·International Journal of Urology : Official Journal of the Japanese Urological Association·Yoshiyuki KakehiOsamu Ogawa
Jun 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy D GilliganUNKNOWN American Society of Clinical Oncology
Jul 25, 2007·Oncology·Dimitrios PectasidesMelina Pectasides
Dec 10, 1999·Seminars in Surgical Oncology·A J Lawton, G M Mead
Jul 23, 1998·Australian and New Zealand Journal of Medicine·J A Levi
Mar 14, 2003·European Journal of Nuclear Medicine and Molecular Imaging·U LassenM Rørth
Mar 16, 2006·BJU International·Gedske DaugaardPeter Sommer
Dec 17, 1998·International Journal of Urology : Official Journal of the Japanese Urological Association·K SuzukiY Ogata
Apr 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gordon J RustinUNKNOWN National Cancer Research Institute Testis Cancer Clinical Studies Group
Dec 5, 2014·World Journal of Urology·Xiangdong LiZhuowei Liu
Dec 16, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Glenda ScanduraDaniel M Berney
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D J SonneveldH J Hoekstra
Jan 5, 2002·Annales D'urologie·A DebbaghS Benjelloun
Apr 1, 1996·Critical Reviews in Oncology/hematology·S CulineJ P Droz
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L HarveyK Tung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.